JD Health International Inc. reported a marginal expansion of its issued share base for August 2026, driven solely by grants under its Post-IPO Share Award Scheme.

Key Takeaways

1. Issued Share Movement • Opening balance (31 July 2026): 3.19 billion ordinary shares. • New shares issued: 0.95 million (+0.03%) through the Post-IPO Share Award Scheme adopted on 23 November 2020. • Closing balance (31 August 2026): 3.19 billion ordinary shares. • No treasury shares were held or cancelled during the month.

2. Authorised Capital Stable • Authorised share capital remained unchanged at 100.00 billion ordinary shares with a par value of USD 0.0000005, representing total authorised capital of USD 50,000.

3. Equity Incentive Schemes • Pre-IPO ESOP: 9.43 million options outstanding after a nominal lapse of 44 options; no new grants or exercises, and no associated capital raise. • Post-IPO Share Option Scheme: no options outstanding, leaving capacity for up to 312.71 million new shares. • Post-IPO Share Award Scheme: 0.95 million shares issued; 13.78 million shares remain available for future awards.

4. Public Float Compliance JD Health confirmed adherence to the Main Board’s minimum 25% public float requirement as at 31 August 2026.

Funding Impact No cash proceeds were generated from the month’s equity movements because the new shares related to the share award scheme were issued without option exercise payments.

Conclusion August’s activity resulted in a modest 0.03% increase in JD Health’s total issued share capital, with no change to authorised capital or treasury share levels. The company retains significant headroom under its Post-IPO Share Option Scheme for future equity-based incentives while maintaining regulatory public float thresholds.